Immunotherapy for lung cancer: for whom the bell tolls?

详细信息    查看全文

• 作者：Pedro Madureira ; Ramon Andrade de Mello ; Alessandro de Vasconcelos…
• 关键词：Lung cancer ; Immunotherapy ; CTLA ; 4 ; Ipilimumab ; Nivolumab ; Pembrolizumab ; Dendritic cells ; PD ; 1 ; Anti ; PD ; L1
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：36
• 期：3
• 页码：1411-1422
• 全文大小：1,221 KB
• 参考文献：Annual smoking-attributable mortality, years of potential life lost, and productivity losses–United States, 1997-001. MMWR Morb Mortal Wkly Rep 54: pp. 625-8
  1. Cokkinides, V, Bandi, P, McMahon, C, Jemal, A, Glynn, T, Ward, E (2009) Tobacco control in the United States—recent progress and opportunities. CA Cancer J Clin 59: pp. 352-65
  2. Jemal, A, Thomas, A, Murray, T, Thun, M (2002) Cancer statistics, 2002. CA Cancer J Clin 52: pp. 23-47
  3. Myers, ML (2013) The FCTC’s evidence-based policies remain a key to ending the tobacco epidemic. Tob Control 22: pp. i45-6
  4. Mulshine, JL (2003) Screening for lung cancer: in pursuit of pre-metastatic disease. Nat Rev Cancer 3: pp. 65-73
  5. Mello, RA, Marques, DS, Medeiros, R, Araujo, AM (2011) Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol 2: pp. 367-76
  6. Felip, E, Stahel, R, Pavlidis, N (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 16: pp. i28-9
  7. Herbst, R, Heymach, J, Lippman, S (2008) Lung cancer. N Engl J Med 359: pp. 1367-80
  8. Drilon, A, Rekhtman, N, Ladanyi, M, Paik, P (2012) Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 13: pp. e418-26
  9. Sharma, SV, Bell, DW, Settleman, J, Haber, DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: pp. 169-81
  10. Mello, RA, Pires, FS, Marques, DS, Oliveira, J, Rodrigues, A, Soares, M (2012) EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumour Biol.
  11. Dienstmann, R, Martinez, P, Felip, E (2011) Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2: pp. 165-77
  12. Jemal, A, Bray, F, Center, M, Ferlay, J, Ward, E, Forman, D (2011) Global cancer statistics. CA Cancer J Clin 61: pp. 69-90
  13. Sculier, J, Chansky, K, Crowley, J, Meerbeeck, J, Goldstraw, P (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 3: pp. 457-66
  14. Nicholson, RI, Gee, JM, Harper, ME (2001) EGFR and cancer prognosis. Eur J Cancer 37: pp. S9-15
  15. Hirsch, FR, Varella-Garcia, M, Bunn, PA, Maria, MV, Veve, R, Bremmes, RM (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol Off J Am Soc Clin Oncol 21: pp. 3798-807
  16. Ohsaki, Y, Tanno, S, Fujita, Y, Toyoshima, E, Fujiuchi, S, Nishigaki, Y (2000) Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7: pp. 603-7
  17. Mello, RA, Madureira, P, Carvalho, LS, Araujo, A, O’Brien, M, Popat, S (2013) EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics 14: pp. 1765-77
  18. Mello, RA (2014) Genetic polymorphisms and non-small-cell lung cancer: future paradigms. Einstein (S?o Paulo) 12: pp. 524-6
  19. Krause, D, Etten, R (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: pp. 172-87
  20. Shepherd, F, Rodrigues Pereira, J, Ciuleanu, T, Tan, E, Hirsh, V, Thongprasert, S (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: pp. 123-32
  21. Lynch, T, Bell, D, Sordella, R, Gurubhagavatula, S, Okimoto, R, Brannigan, B (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: pp. 2129-39
  22. Cappuzzo, F, Hirsch, F, Rossi, E, Bartolini, S, Ceresoli, G, Bemis, L (2005) Epidermal growth factor receptor gene and protein and gefi tinib sensitivity in non-small-cell lung cancer. J Nat Cancer Inst 97: pp. 643-55
  23. Brundage, M, Davies, D, Mackillop, W (2002) Prognostic factors in non-small cell lung cancer. Chest 122: pp. 1037-57
  24. Flajnik, MF, Kasahara, M (2010) Origin and evolution of the adaptive immune system: genetic events and selective pressures. Nat Rev Genet 11: pp. 47-59
  25. Lanzavecchia, A, Sallusto, F (2001) Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol 2: pp. 487-92
  26. Li, QJ, Dinner, AR, Qi, S, Irvine, DJ, Huppa, JB, Davis, MM (2004) CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. Nat Immunol 5: pp. 791-9
  27. Schwartz, JC, Zhang, X, Nathenson, SG, Almo, SC (2002) Structural mechanisms of costimulation. Nat Immunol 3: pp. 427-34
  28. Josefowi
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Lung cancer is the leading cause of cancer-related death and accounts for approximately 30?% of all cancer deaths. Despite the recent developments in personalized therapy, the prognosis in lung cancer is still very poor. Immunotherapy is now emerging as a new hope for patients with lung cancer. It is well known that standard chemotherapeutic regimens have devastating effects for the patient’s immune system. Therefore, the aim of immunotherapy is to specifically enhance the immune response against the tumour. Recently, many trials addressed the role of such therapies for metastatic non-small cell lung cancer (NSCLC) treatment: ipilimumab, tremelimumab, nivolumab and pembrolizumab are immunotherapeutic agents of high relevance in this field. Anti-tumour vaccines, as well as dendritic cell-based therapies, have emerged as potent inducers of immune response against the tumour. Herein, we will review some of the most promising cancer immunotherapies, highlighting their advantages and try to understand, in an immunological perspective, the missteps associated with the current treatments for cancer.